Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.
Identifieur interne : 001F99 ( PubMed/Checkpoint ); précédent : 001F98; suivant : 002000Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.
Auteurs : Larry A. Greenbaum [États-Unis] ; Marc Fila [France] ; Gianluigi Ardissino [Italie] ; Samhar I. Al-Akash [États-Unis] ; Jonathan Evans [Royaume-Uni] ; Paul Henning [Australie] ; Kenneth V. Lieberman [États-Unis] ; Silvio Maringhini [Italie] ; Lars Pape [Allemagne] ; Lesley Rees [Royaume-Uni] ; Nicole C A J. Van De Kar [Pays-Bas] ; Johan Vande Walle [Belgique] ; Masayo Ogawa [États-Unis] ; Camille L. Bedrosian [États-Unis] ; Christoph Licht [Canada]Source :
- Kidney international [ 1523-1755 ] ; 2016.
Descripteurs français
- KwdFr :
- Activation du complément (), Adolescent, Amérique du Nord, Anticorps monoclonaux humanisés (effets indésirables), Anticorps monoclonaux humanisés (pharmacocinétique), Anticorps monoclonaux humanisés (usage thérapeutique), Australie, Dialyse rénale, Enfant, Enfant d'âge préscolaire, Europe, Facteurs de l'âge, Facteurs temps, Femelle, Humains, Inhibiteurs du complément (effets indésirables), Inhibiteurs du complément (pharmacocinétique), Inhibiteurs du complément (usage thérapeutique), Mâle, Nourrisson, Résultat thérapeutique, Syndrome hémolytique et urémique atypique (diagnostic), Syndrome hémolytique et urémique atypique (immunologie), Syndrome hémolytique et urémique atypique (traitement médicamenteux), Échange plasmatique, Études prospectives.
- MESH :
- diagnostic : Syndrome hémolytique et urémique atypique.
- effets indésirables : Anticorps monoclonaux humanisés, Inhibiteurs du complément.
- immunologie : Syndrome hémolytique et urémique atypique.
- pharmacocinétique : Anticorps monoclonaux humanisés, Inhibiteurs du complément.
- traitement médicamenteux : Syndrome hémolytique et urémique atypique.
- usage thérapeutique : Anticorps monoclonaux humanisés, Inhibiteurs du complément.
- Activation du complément, Adolescent, Amérique du Nord, Australie, Dialyse rénale, Enfant, Enfant d'âge préscolaire, Europe, Facteurs de l'âge, Facteurs temps, Femelle, Humains, Mâle, Nourrisson, Résultat thérapeutique, Échange plasmatique, Études prospectives.
English descriptors
- KwdEn :
- Adolescent, Age Factors, Antibodies, Monoclonal, Humanized (adverse effects), Antibodies, Monoclonal, Humanized (pharmacokinetics), Antibodies, Monoclonal, Humanized (therapeutic use), Atypical Hemolytic Uremic Syndrome (diagnosis), Atypical Hemolytic Uremic Syndrome (drug therapy), Atypical Hemolytic Uremic Syndrome (immunology), Australia, Child, Child, Preschool, Complement Activation (drug effects), Complement Inactivating Agents (adverse effects), Complement Inactivating Agents (pharmacokinetics), Complement Inactivating Agents (therapeutic use), Europe, Female, Humans, Infant, Male, North America, Plasma Exchange, Prospective Studies, Renal Dialysis, Time Factors, Treatment Outcome.
- MESH :
- chemical , adverse effects : Antibodies, Monoclonal, Humanized, Complement Inactivating Agents.
- chemical , pharmacokinetics : Antibodies, Monoclonal, Humanized, Complement Inactivating Agents.
- chemical , therapeutic use : Antibodies, Monoclonal, Humanized, Complement Inactivating Agents.
- diagnosis : Atypical Hemolytic Uremic Syndrome.
- drug effects : Complement Activation.
- drug therapy : Atypical Hemolytic Uremic Syndrome.
- immunology : Atypical Hemolytic Uremic Syndrome.
- Adolescent, Age Factors, Australia, Child, Child, Preschool, Europe, Female, Humans, Infant, Male, North America, Plasma Exchange, Prospective Studies, Renal Dialysis, Time Factors, Treatment Outcome.
Abstract
Atypical hemolytic uremic syndrome (aHUS) is caused by alternative complement pathway dysregulation, leading to systemic thrombotic microangiopathy (TMA) and severe end-organ damage. Based on 2 prospective studies in mostly adults and retrospective data in children, eculizumab, a terminal complement inhibitor, is approved for aHUS treatment. Here we prospectively evaluated efficacy and safety of weight-based dosing of eculizumab in eligible pediatric patients with aHUS in an open-label phase II study. The primary end point was complete TMA response by 26 weeks. Twenty-two patients (aged 5 months-17 years) were treated; 16 were newly diagnosed, 12 had no prior plasma exchange/infusion during current TMA symptomatology, 11 received baseline dialysis and 2 had prior renal transplants. By week 26, 14 achieved a complete TMA response, 18 achieved hematologic normalization, and 16 had 25% or better improvement in serum creatinine. Plasma exchange/infusion was discontinued in all, and 9 of the 11 patients who required dialysis at baseline discontinued, whereas none initiated new dialysis. Eculizumab was well tolerated; no deaths or meningococcal infections occurred. Bone marrow failure, wrist fracture, and acute respiratory failure were reported as unrelated severe adverse events. Thus, our findings establish the efficacy and safety of eculizumab for pediatric patients with aHUS and are consistent with proposed immediate eculizumab initiation following diagnosis in children.
DOI: 10.1016/j.kint.2015.11.026
PubMed: 26880462
Affiliations:
- Allemagne, Australie, Belgique, Canada, France, Italie, Pays-Bas, Royaume-Uni, États-Unis
- Angleterre, Basse-Saxe, Connecticut, Grand Londres, Gueldre, Géorgie (États-Unis), Languedoc-Roussillon, Lombardie, New Jersey, Occitanie (région administrative), Texas
- Hanovre, Londres, Milan, Montpellier, Nimègue
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:26880462Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.</title><author><name sortKey="Greenbaum, Larry A" sort="Greenbaum, Larry A" uniqKey="Greenbaum L" first="Larry A" last="Greenbaum">Larry A. Greenbaum</name><affiliation wicri:level="2"><nlm:affiliation>Emory University and Children's Healthcare of Atlanta, Atlanta, Georgia, USA. Electronic address: lgreen6@emory.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Emory University and Children's Healthcare of Atlanta, Atlanta, Georgia</wicri:regionArea><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="Fila, Marc" sort="Fila, Marc" uniqKey="Fila M" first="Marc" last="Fila">Marc Fila</name><affiliation wicri:level="3"><nlm:affiliation>CHRU de Montpellier - Hôpital Arnaud de Villeneuve, Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CHRU de Montpellier - Hôpital Arnaud de Villeneuve, Montpellier</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Ardissino, Gianluigi" sort="Ardissino, Gianluigi" uniqKey="Ardissino G" first="Gianluigi" last="Ardissino">Gianluigi Ardissino</name><affiliation wicri:level="3"><nlm:affiliation>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Al Akash, Samhar I" sort="Al Akash, Samhar I" uniqKey="Al Akash S" first="Samhar I" last="Al-Akash">Samhar I. Al-Akash</name><affiliation wicri:level="2"><nlm:affiliation>Driscoll Children's Hospital, Corpus Christi, Texas, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Driscoll Children's Hospital, Corpus Christi, Texas</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Evans, Jonathan" sort="Evans, Jonathan" uniqKey="Evans J" first="Jonathan" last="Evans">Jonathan Evans</name><affiliation wicri:level="1"><nlm:affiliation>Nottingham University Hospitals, Nottingham, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Nottingham University Hospitals, Nottingham</wicri:regionArea><wicri:noRegion>Nottingham</wicri:noRegion></affiliation></author><author><name sortKey="Henning, Paul" sort="Henning, Paul" uniqKey="Henning P" first="Paul" last="Henning">Paul Henning</name><affiliation wicri:level="1"><nlm:affiliation>Women's and Children's Hospital, North Adelaide, South Australia, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Women's and Children's Hospital, North Adelaide, South Australia</wicri:regionArea><wicri:noRegion>South Australia</wicri:noRegion></affiliation></author><author><name sortKey="Lieberman, Kenneth V" sort="Lieberman, Kenneth V" uniqKey="Lieberman K" first="Kenneth V" last="Lieberman">Kenneth V. Lieberman</name><affiliation wicri:level="2"><nlm:affiliation>Hackensack University Medical Center, Hackensack, New Jersey, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Hackensack University Medical Center, Hackensack, New Jersey</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Maringhini, Silvio" sort="Maringhini, Silvio" uniqKey="Maringhini S" first="Silvio" last="Maringhini">Silvio Maringhini</name><affiliation wicri:level="1"><nlm:affiliation>G. Di Cristina Children's Hospital, Palermo, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>G. Di Cristina Children's Hospital, Palermo</wicri:regionArea><wicri:noRegion>Palermo</wicri:noRegion></affiliation></author><author><name sortKey="Pape, Lars" sort="Pape, Lars" uniqKey="Pape L" first="Lars" last="Pape">Lars Pape</name><affiliation wicri:level="3"><nlm:affiliation>Hannover Medical School, Hannover, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Hannover Medical School, Hannover</wicri:regionArea><placeName><region type="land" nuts="2">Basse-Saxe</region><settlement type="city">Hanovre</settlement></placeName></affiliation></author><author><name sortKey="Rees, Lesley" sort="Rees, Lesley" uniqKey="Rees L" first="Lesley" last="Rees">Lesley Rees</name><affiliation wicri:level="3"><nlm:affiliation>Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Great Ormond Street Hospital for Children NHS Foundation Trust, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Van De Kar, Nicole C A J" sort="Van De Kar, Nicole C A J" uniqKey="Van De Kar N" first="Nicole C A J" last="Van De Kar">Nicole C A J. Van De Kar</name><affiliation wicri:level="3"><nlm:affiliation>Radboud University Medical Centre, Nijmegen, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Radboud University Medical Centre, Nijmegen</wicri:regionArea><placeName><settlement type="city">Nimègue</settlement><region type="province" nuts="2">Gueldre</region></placeName></affiliation></author><author><name sortKey="Vande Walle, Johan" sort="Vande Walle, Johan" uniqKey="Vande Walle J" first="Johan" last="Vande Walle">Johan Vande Walle</name><affiliation wicri:level="1"><nlm:affiliation>University Hospital Ghent, Ghent, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>University Hospital Ghent, Ghent</wicri:regionArea><wicri:noRegion>Ghent</wicri:noRegion></affiliation></author><author><name sortKey="Ogawa, Masayo" sort="Ogawa, Masayo" uniqKey="Ogawa M" first="Masayo" last="Ogawa">Masayo Ogawa</name><affiliation wicri:level="2"><nlm:affiliation>Alexion Pharmaceuticals, Inc., Cheshire, Connecticut, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Alexion Pharmaceuticals, Inc., Cheshire, Connecticut</wicri:regionArea><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Bedrosian, Camille L" sort="Bedrosian, Camille L" uniqKey="Bedrosian C" first="Camille L" last="Bedrosian">Camille L. Bedrosian</name><affiliation wicri:level="2"><nlm:affiliation>Alexion Pharmaceuticals, Inc., Cheshire, Connecticut, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Alexion Pharmaceuticals, Inc., Cheshire, Connecticut</wicri:regionArea><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Licht, Christoph" sort="Licht, Christoph" uniqKey="Licht C" first="Christoph" last="Licht">Christoph Licht</name><affiliation wicri:level="1"><nlm:affiliation>The Hospital for Sick Children, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>The Hospital for Sick Children, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26880462</idno><idno type="pmid">26880462</idno><idno type="doi">10.1016/j.kint.2015.11.026</idno><idno type="wicri:Area/PubMed/Corpus">002128</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002128</idno><idno type="wicri:Area/PubMed/Curation">002102</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002102</idno><idno type="wicri:Area/PubMed/Checkpoint">002102</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002102</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.</title><author><name sortKey="Greenbaum, Larry A" sort="Greenbaum, Larry A" uniqKey="Greenbaum L" first="Larry A" last="Greenbaum">Larry A. Greenbaum</name><affiliation wicri:level="2"><nlm:affiliation>Emory University and Children's Healthcare of Atlanta, Atlanta, Georgia, USA. Electronic address: lgreen6@emory.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Emory University and Children's Healthcare of Atlanta, Atlanta, Georgia</wicri:regionArea><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="Fila, Marc" sort="Fila, Marc" uniqKey="Fila M" first="Marc" last="Fila">Marc Fila</name><affiliation wicri:level="3"><nlm:affiliation>CHRU de Montpellier - Hôpital Arnaud de Villeneuve, Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CHRU de Montpellier - Hôpital Arnaud de Villeneuve, Montpellier</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Ardissino, Gianluigi" sort="Ardissino, Gianluigi" uniqKey="Ardissino G" first="Gianluigi" last="Ardissino">Gianluigi Ardissino</name><affiliation wicri:level="3"><nlm:affiliation>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Al Akash, Samhar I" sort="Al Akash, Samhar I" uniqKey="Al Akash S" first="Samhar I" last="Al-Akash">Samhar I. Al-Akash</name><affiliation wicri:level="2"><nlm:affiliation>Driscoll Children's Hospital, Corpus Christi, Texas, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Driscoll Children's Hospital, Corpus Christi, Texas</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Evans, Jonathan" sort="Evans, Jonathan" uniqKey="Evans J" first="Jonathan" last="Evans">Jonathan Evans</name><affiliation wicri:level="1"><nlm:affiliation>Nottingham University Hospitals, Nottingham, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Nottingham University Hospitals, Nottingham</wicri:regionArea><wicri:noRegion>Nottingham</wicri:noRegion></affiliation></author><author><name sortKey="Henning, Paul" sort="Henning, Paul" uniqKey="Henning P" first="Paul" last="Henning">Paul Henning</name><affiliation wicri:level="1"><nlm:affiliation>Women's and Children's Hospital, North Adelaide, South Australia, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Women's and Children's Hospital, North Adelaide, South Australia</wicri:regionArea><wicri:noRegion>South Australia</wicri:noRegion></affiliation></author><author><name sortKey="Lieberman, Kenneth V" sort="Lieberman, Kenneth V" uniqKey="Lieberman K" first="Kenneth V" last="Lieberman">Kenneth V. Lieberman</name><affiliation wicri:level="2"><nlm:affiliation>Hackensack University Medical Center, Hackensack, New Jersey, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Hackensack University Medical Center, Hackensack, New Jersey</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Maringhini, Silvio" sort="Maringhini, Silvio" uniqKey="Maringhini S" first="Silvio" last="Maringhini">Silvio Maringhini</name><affiliation wicri:level="1"><nlm:affiliation>G. Di Cristina Children's Hospital, Palermo, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>G. Di Cristina Children's Hospital, Palermo</wicri:regionArea><wicri:noRegion>Palermo</wicri:noRegion></affiliation></author><author><name sortKey="Pape, Lars" sort="Pape, Lars" uniqKey="Pape L" first="Lars" last="Pape">Lars Pape</name><affiliation wicri:level="3"><nlm:affiliation>Hannover Medical School, Hannover, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Hannover Medical School, Hannover</wicri:regionArea><placeName><region type="land" nuts="2">Basse-Saxe</region><settlement type="city">Hanovre</settlement></placeName></affiliation></author><author><name sortKey="Rees, Lesley" sort="Rees, Lesley" uniqKey="Rees L" first="Lesley" last="Rees">Lesley Rees</name><affiliation wicri:level="3"><nlm:affiliation>Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Great Ormond Street Hospital for Children NHS Foundation Trust, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Van De Kar, Nicole C A J" sort="Van De Kar, Nicole C A J" uniqKey="Van De Kar N" first="Nicole C A J" last="Van De Kar">Nicole C A J. Van De Kar</name><affiliation wicri:level="3"><nlm:affiliation>Radboud University Medical Centre, Nijmegen, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Radboud University Medical Centre, Nijmegen</wicri:regionArea><placeName><settlement type="city">Nimègue</settlement><region type="province" nuts="2">Gueldre</region></placeName></affiliation></author><author><name sortKey="Vande Walle, Johan" sort="Vande Walle, Johan" uniqKey="Vande Walle J" first="Johan" last="Vande Walle">Johan Vande Walle</name><affiliation wicri:level="1"><nlm:affiliation>University Hospital Ghent, Ghent, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>University Hospital Ghent, Ghent</wicri:regionArea><wicri:noRegion>Ghent</wicri:noRegion></affiliation></author><author><name sortKey="Ogawa, Masayo" sort="Ogawa, Masayo" uniqKey="Ogawa M" first="Masayo" last="Ogawa">Masayo Ogawa</name><affiliation wicri:level="2"><nlm:affiliation>Alexion Pharmaceuticals, Inc., Cheshire, Connecticut, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Alexion Pharmaceuticals, Inc., Cheshire, Connecticut</wicri:regionArea><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Bedrosian, Camille L" sort="Bedrosian, Camille L" uniqKey="Bedrosian C" first="Camille L" last="Bedrosian">Camille L. Bedrosian</name><affiliation wicri:level="2"><nlm:affiliation>Alexion Pharmaceuticals, Inc., Cheshire, Connecticut, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Alexion Pharmaceuticals, Inc., Cheshire, Connecticut</wicri:regionArea><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Licht, Christoph" sort="Licht, Christoph" uniqKey="Licht C" first="Christoph" last="Licht">Christoph Licht</name><affiliation wicri:level="1"><nlm:affiliation>The Hospital for Sick Children, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>The Hospital for Sick Children, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author></analytic><series><title level="j">Kidney international</title><idno type="eISSN">1523-1755</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Age Factors</term><term>Antibodies, Monoclonal, Humanized (adverse effects)</term><term>Antibodies, Monoclonal, Humanized (pharmacokinetics)</term><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Atypical Hemolytic Uremic Syndrome (diagnosis)</term><term>Atypical Hemolytic Uremic Syndrome (drug therapy)</term><term>Atypical Hemolytic Uremic Syndrome (immunology)</term><term>Australia</term><term>Child</term><term>Child, Preschool</term><term>Complement Activation (drug effects)</term><term>Complement Inactivating Agents (adverse effects)</term><term>Complement Inactivating Agents (pharmacokinetics)</term><term>Complement Inactivating Agents (therapeutic use)</term><term>Europe</term><term>Female</term><term>Humans</term><term>Infant</term><term>Male</term><term>North America</term><term>Plasma Exchange</term><term>Prospective Studies</term><term>Renal Dialysis</term><term>Time Factors</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Activation du complément ()</term><term>Adolescent</term><term>Amérique du Nord</term><term>Anticorps monoclonaux humanisés (effets indésirables)</term><term>Anticorps monoclonaux humanisés (pharmacocinétique)</term><term>Anticorps monoclonaux humanisés (usage thérapeutique)</term><term>Australie</term><term>Dialyse rénale</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Europe</term><term>Facteurs de l'âge</term><term>Facteurs temps</term><term>Femelle</term><term>Humains</term><term>Inhibiteurs du complément (effets indésirables)</term><term>Inhibiteurs du complément (pharmacocinétique)</term><term>Inhibiteurs du complément (usage thérapeutique)</term><term>Mâle</term><term>Nourrisson</term><term>Résultat thérapeutique</term><term>Syndrome hémolytique et urémique atypique (diagnostic)</term><term>Syndrome hémolytique et urémique atypique (immunologie)</term><term>Syndrome hémolytique et urémique atypique (traitement médicamenteux)</term><term>Échange plasmatique</term><term>Études prospectives</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term><term>Complement Inactivating Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term><term>Complement Inactivating Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term><term>Complement Inactivating Agents</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Atypical Hemolytic Uremic Syndrome</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Syndrome hémolytique et urémique atypique</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Complement Activation</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Atypical Hemolytic Uremic Syndrome</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term><term>Inhibiteurs du complément</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Syndrome hémolytique et urémique atypique</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Atypical Hemolytic Uremic Syndrome</term></keywords><keywords scheme="MESH" qualifier="pharmacocinétique" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term><term>Inhibiteurs du complément</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Syndrome hémolytique et urémique atypique</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term><term>Inhibiteurs du complément</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Age Factors</term><term>Australia</term><term>Child</term><term>Child, Preschool</term><term>Europe</term><term>Female</term><term>Humans</term><term>Infant</term><term>Male</term><term>North America</term><term>Plasma Exchange</term><term>Prospective Studies</term><term>Renal Dialysis</term><term>Time Factors</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Activation du complément</term><term>Adolescent</term><term>Amérique du Nord</term><term>Australie</term><term>Dialyse rénale</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Europe</term><term>Facteurs de l'âge</term><term>Facteurs temps</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Nourrisson</term><term>Résultat thérapeutique</term><term>Échange plasmatique</term><term>Études prospectives</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Atypical hemolytic uremic syndrome (aHUS) is caused by alternative complement pathway dysregulation, leading to systemic thrombotic microangiopathy (TMA) and severe end-organ damage. Based on 2 prospective studies in mostly adults and retrospective data in children, eculizumab, a terminal complement inhibitor, is approved for aHUS treatment. Here we prospectively evaluated efficacy and safety of weight-based dosing of eculizumab in eligible pediatric patients with aHUS in an open-label phase II study. The primary end point was complete TMA response by 26 weeks. Twenty-two patients (aged 5 months-17 years) were treated; 16 were newly diagnosed, 12 had no prior plasma exchange/infusion during current TMA symptomatology, 11 received baseline dialysis and 2 had prior renal transplants. By week 26, 14 achieved a complete TMA response, 18 achieved hematologic normalization, and 16 had 25% or better improvement in serum creatinine. Plasma exchange/infusion was discontinued in all, and 9 of the 11 patients who required dialysis at baseline discontinued, whereas none initiated new dialysis. Eculizumab was well tolerated; no deaths or meningococcal infections occurred. Bone marrow failure, wrist fracture, and acute respiratory failure were reported as unrelated severe adverse events. Thus, our findings establish the efficacy and safety of eculizumab for pediatric patients with aHUS and are consistent with proposed immediate eculizumab initiation following diagnosis in children.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26880462</PMID><DateCreated><Year>2016</Year><Month>02</Month><Day>16</Day></DateCreated><DateCompleted><Year>2016</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2016</Year><Month>12</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1523-1755</ISSN><JournalIssue CitedMedium="Internet"><Volume>89</Volume><Issue>3</Issue><PubDate><Year>2016</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Kidney international</Title><ISOAbbreviation>Kidney Int.</ISOAbbreviation></Journal><ArticleTitle>Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.</ArticleTitle><Pagination><MedlinePgn>701-11</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.kint.2015.11.026</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0085-2538(15)00182-9</ELocationID><Abstract><AbstractText>Atypical hemolytic uremic syndrome (aHUS) is caused by alternative complement pathway dysregulation, leading to systemic thrombotic microangiopathy (TMA) and severe end-organ damage. Based on 2 prospective studies in mostly adults and retrospective data in children, eculizumab, a terminal complement inhibitor, is approved for aHUS treatment. Here we prospectively evaluated efficacy and safety of weight-based dosing of eculizumab in eligible pediatric patients with aHUS in an open-label phase II study. The primary end point was complete TMA response by 26 weeks. Twenty-two patients (aged 5 months-17 years) were treated; 16 were newly diagnosed, 12 had no prior plasma exchange/infusion during current TMA symptomatology, 11 received baseline dialysis and 2 had prior renal transplants. By week 26, 14 achieved a complete TMA response, 18 achieved hematologic normalization, and 16 had 25% or better improvement in serum creatinine. Plasma exchange/infusion was discontinued in all, and 9 of the 11 patients who required dialysis at baseline discontinued, whereas none initiated new dialysis. Eculizumab was well tolerated; no deaths or meningococcal infections occurred. Bone marrow failure, wrist fracture, and acute respiratory failure were reported as unrelated severe adverse events. Thus, our findings establish the efficacy and safety of eculizumab for pediatric patients with aHUS and are consistent with proposed immediate eculizumab initiation following diagnosis in children.</AbstractText><CopyrightInformation>Copyright © 2016 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Greenbaum</LastName><ForeName>Larry A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Emory University and Children's Healthcare of Atlanta, Atlanta, Georgia, USA. Electronic address: lgreen6@emory.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fila</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>CHRU de Montpellier - Hôpital Arnaud de Villeneuve, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ardissino</LastName><ForeName>Gianluigi</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Akash</LastName><ForeName>Samhar I</ForeName><Initials>SI</Initials><AffiliationInfo><Affiliation>Driscoll Children's Hospital, Corpus Christi, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Evans</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Nottingham University Hospitals, Nottingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henning</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Women's and Children's Hospital, North Adelaide, South Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lieberman</LastName><ForeName>Kenneth V</ForeName><Initials>KV</Initials><AffiliationInfo><Affiliation>Hackensack University Medical Center, Hackensack, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maringhini</LastName><ForeName>Silvio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>G. Di Cristina Children's Hospital, Palermo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pape</LastName><ForeName>Lars</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rees</LastName><ForeName>Lesley</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van de Kar</LastName><ForeName>Nicole C A J</ForeName><Initials>NC</Initials><AffiliationInfo><Affiliation>Radboud University Medical Centre, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vande Walle</LastName><ForeName>Johan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University Hospital Ghent, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ogawa</LastName><ForeName>Masayo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Alexion Pharmaceuticals, Inc., Cheshire, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bedrosian</LastName><ForeName>Camille L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Alexion Pharmaceuticals, Inc., Cheshire, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Licht</LastName><ForeName>Christoph</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>The Hospital for Sick Children, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>01</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Kidney Int</MedlineTA><NlmUniqueID>0323470</NlmUniqueID><ISSNLinking>0085-2538</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051056">Complement Inactivating Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>A3ULP0F556</RegistryNumber><NameOfSubstance UI="C481642">eculizumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Kidney Int. 2016 Mar;89(3):537-8</RefSource><PMID Version="1">26880449</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065766" MajorTopicYN="N">Atypical Hemolytic Uremic Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001315" MajorTopicYN="N">Australia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003167" MajorTopicYN="N">Complement Activation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051056" MajorTopicYN="N">Complement Inactivating Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N">Europe</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009656" MajorTopicYN="N">North America</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010951" MajorTopicYN="N">Plasma Exchange</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006435" MajorTopicYN="N">Renal Dialysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">aHUS</Keyword><Keyword MajorTopicYN="N">children</Keyword><Keyword MajorTopicYN="N">eculizumab</Keyword><Keyword MajorTopicYN="N">kidney disease</Keyword><Keyword MajorTopicYN="N">pediatric</Keyword><Keyword MajorTopicYN="N">thrombotic microangiopathy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>03</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>11</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>2</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26880462</ArticleId><ArticleId IdType="pii">S0085-2538(15)00182-9</ArticleId><ArticleId IdType="doi">10.1016/j.kint.2015.11.026</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Belgique</li><li>Canada</li><li>France</li><li>Italie</li><li>Pays-Bas</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Basse-Saxe</li><li>Connecticut</li><li>Grand Londres</li><li>Gueldre</li><li>Géorgie (États-Unis)</li><li>Languedoc-Roussillon</li><li>Lombardie</li><li>New Jersey</li><li>Occitanie (région administrative)</li><li>Texas</li></region><settlement><li>Hanovre</li><li>Londres</li><li>Milan</li><li>Montpellier</li><li>Nimègue</li></settlement></list><tree><country name="États-Unis"><region name="Géorgie (États-Unis)"><name sortKey="Greenbaum, Larry A" sort="Greenbaum, Larry A" uniqKey="Greenbaum L" first="Larry A" last="Greenbaum">Larry A. Greenbaum</name></region><name sortKey="Al Akash, Samhar I" sort="Al Akash, Samhar I" uniqKey="Al Akash S" first="Samhar I" last="Al-Akash">Samhar I. Al-Akash</name><name sortKey="Bedrosian, Camille L" sort="Bedrosian, Camille L" uniqKey="Bedrosian C" first="Camille L" last="Bedrosian">Camille L. Bedrosian</name><name sortKey="Lieberman, Kenneth V" sort="Lieberman, Kenneth V" uniqKey="Lieberman K" first="Kenneth V" last="Lieberman">Kenneth V. Lieberman</name><name sortKey="Ogawa, Masayo" sort="Ogawa, Masayo" uniqKey="Ogawa M" first="Masayo" last="Ogawa">Masayo Ogawa</name></country><country name="France"><region name="Occitanie (région administrative)"><name sortKey="Fila, Marc" sort="Fila, Marc" uniqKey="Fila M" first="Marc" last="Fila">Marc Fila</name></region></country><country name="Italie"><region name="Lombardie"><name sortKey="Ardissino, Gianluigi" sort="Ardissino, Gianluigi" uniqKey="Ardissino G" first="Gianluigi" last="Ardissino">Gianluigi Ardissino</name></region><name sortKey="Maringhini, Silvio" sort="Maringhini, Silvio" uniqKey="Maringhini S" first="Silvio" last="Maringhini">Silvio Maringhini</name></country><country name="Royaume-Uni"><noRegion><name sortKey="Evans, Jonathan" sort="Evans, Jonathan" uniqKey="Evans J" first="Jonathan" last="Evans">Jonathan Evans</name></noRegion><name sortKey="Rees, Lesley" sort="Rees, Lesley" uniqKey="Rees L" first="Lesley" last="Rees">Lesley Rees</name></country><country name="Australie"><noRegion><name sortKey="Henning, Paul" sort="Henning, Paul" uniqKey="Henning P" first="Paul" last="Henning">Paul Henning</name></noRegion></country><country name="Allemagne"><region name="Basse-Saxe"><name sortKey="Pape, Lars" sort="Pape, Lars" uniqKey="Pape L" first="Lars" last="Pape">Lars Pape</name></region></country><country name="Pays-Bas"><region name="Gueldre"><name sortKey="Van De Kar, Nicole C A J" sort="Van De Kar, Nicole C A J" uniqKey="Van De Kar N" first="Nicole C A J" last="Van De Kar">Nicole C A J. Van De Kar</name></region></country><country name="Belgique"><noRegion><name sortKey="Vande Walle, Johan" sort="Vande Walle, Johan" uniqKey="Vande Walle J" first="Johan" last="Vande Walle">Johan Vande Walle</name></noRegion></country><country name="Canada"><noRegion><name sortKey="Licht, Christoph" sort="Licht, Christoph" uniqKey="Licht C" first="Christoph" last="Licht">Christoph Licht</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F99 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001F99 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:26880462
|texte= Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:26880462" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |